Karyopharm Therapeutics | KPTI - Sales Revenues


Karyopharm Therapeutics reported $35.07M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Abbott USD 12.59B 1.43B Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Incyte USD 1.67B 400M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.6B 310M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Takeda JPY 1.22T 130B Jun/2026
Tectonic Therapeutic USD 0 0 Dec/2024
TG Therapeutics USD 240.34M 45.54M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026